Scrip code	5245	502
NSE Symbol	NO	FLISTED
MSEI Symbol	NO	TLISTED
ISIN	INE	548H01015
Name of the entity	RAA	AJ MEDISAFE INDIA LIMITED
Date of start of financial year	01-0	04-2024
Date of end of financial year	31-0	3-2025
Reporting Quarter Type	Year	ly
Date of Quarter Ending	31-0	03-2025
Type of company	Equi	ity
Whether Annexure I (Part A) of the SEBI Circular dated December 31, 2024 related to Compliance Report on Corporate Governance is applicable to the entity?	Yes	
Whether Annexure I (Part B) of the SEBI Circular dated December 31, 2024 related to Investor Grievance Redressal Report is Applicable to the entity?	Yes	
Whether Annexure I (Part C) of the SEBI Circular dated December 31, 2024 related to Disclosure of Acquisition of Shares or Voting Rights in Unlisted Companies is Applicable to the entity?	No	There is no such acquisition of shares or voting rights in unlisted companies during the quarter in terms of sub-para 1 of para A of Part A of Schedule III of the SEBI (LODR) Regulations, 2015.
Whether Annexure I (Part D) of the SEBI Circular dated December 31, 2024 related to Disclosure of Imposition of Fine or Penalty is Applicable to the entity?	No	2. During the quarter, there are no details of fines and penalties which are lower than Rs. One labimposed by sectoral regulator and Rs.10 lakh if imposed by other judicial bodies/authorities, in t sub-para 20 of Para A of Part A of Schedule III of the SEBI (LODR) Regulations,2015.
Whether Annexure I (Part E) of the SEBI Circular dated December 31, 2024 related to Disclosure of Updates to Ongoing Tax Litigations or Disputes is Applicable to the entity?	No	During the quarter, there was no update in respect of ongoing tax litigations or disputes in terms sub-para 8 of para B of part A of Schedule III of the SEBI (LODR) Regulations,2015. It's the sar as submitted last quarter. The details are as under:- Sr. No. Name of the opposing party Date of initiation of the litigation / dispute Status of the litigation / dispute as per last disclosure Current status of the litigation / dispute 1 National Faceless Appeal Center 24-04-2021 Appeal Proceeding are under process for the Assessment Year 2018-19. The Company has submitted its submission Hon'ble CIT (A) Under Process, Order awaited
Whether Annexure I (Part F) of the SEBI Circular dated December 31, 2024 related to Disclosure Of Loans / Guarantees / Comfort Letters / Securities Etc. is Applicable to the entity?	No	There is no loans/ Guarantees/ comfort letters/ Securities applicable to company in this quarter a half year ended as on 31st March, 2025
Risk management committee	Not	Applicable
Market Capitalisation as per immediate previous Financial Year	Any	other
Is SCORE ID Available?	Yes	
SCORE Registration ID	r004	91
Reason For No SCORE ID		
Type of Submission	Orig	
Remarks (website dissemination)		

				A	annexure I								
	Annexure I to be submitted by listed entity on quarterly basis												
	I. Composition of Board of Directors												
	Disclosure of notes on composition of board of directors explanatory												
	Whether the listed entity has a Regular Chairperson Yes												
	Whether Chairperson is related to MD or CEO No												
Sr	Title (Mr / Ms)	Name of the Director	PAN	DIN	Category 1 of directors  Category 2 of directors		Category 3 of directors	Date of Birth					
1	Mr	ARPIT BANGUR	AKBPB2579C	02600716	Executive Director	Chairperson	MD	30-12- 1987					
2	Mr	NAVIN JHAWAR	AFGPJ7521J	08229821	Executive Director	Not Applicable	MD	15-09- 1981					
3	Mrs	KRISHNA JAJOO	AERPJ9660E	02590793	Non-Executive - Non Independent Director	Not Applicable		28-03- 1952					
4	Mr	RAKESH AGRAWAL	AGIPA2195G	09675176	Non-Executive - Independent Director	Not Applicable		31-01- 1972					
5   Mr     AGAPKOISOBIO1/9/3001						10-01- 1972							
6	Mr	ATEET AGRAWAL	AFOPA1235Q	05167866	Non-Executive - Independent Director	Not Applicable		24-12- 1975					

	I. Composition of Board of Directors											
	Disqualification of Directors under section 164 of the Companies Act, 2013											
Sr	Whether the director is disqualified?	Start Date of disqualification	End Date of disqualification	Details of disqualification	Current status							
1	No				Active							
2	No				Active							
3	No				Active							
4	No				Active							
5	No				Active							
6	No				Active							

					I. Co	ompositi	on of Board	of Directors					
Sr	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Reappointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity [with reference to proviso to regulation 17A(1) & reg. 17A(2)]	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Reason for Cessation	Notes for not providing PAN	Notes for not providing DIN
1	NA		14-08- 2024				1	0	0	0			
2	NA		18-08- 2021				1	0	0	0			
3	NA		15-01- 2015	25-09- 2024			1	0	0	0			
4	NA		09-08- 2022			31.22	1	1	2	1			_
5	NA	_	14-08- 2024			7.17	1	1	2	1			
6	NA		14-08- 2024			7.17	1	1	2	1			

Au	Audit Committee Details												
Sr	DIN Number	Name of Committee members	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks							
1	09675176	RAKESH AGRAWAL	Non-Executive - Independent Director	Member	09-08-2022								
2	01797300	HEMANT KASLIWAL	Non-Executive - Independent Director	Chairperson	17-09-2024								
3	05167866	ATEET AGRAWAL	Non-Executive - Independent Director	Member	17-09-2024								

No	mination an	nd remuneration commit	tee				
	Wh	nether the Nomination and	remuneration committee has a F	Regular Chairperson	Yes		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	09675176	RAKESH AGRAWAL	Non-Executive - Independent Director	Chairperson	09-08-2022		
2	01797300	HEMANT KASLIWAL	Non-Executive - Independent Director	Member	17-09-2024		
3	05167866	ATEET AGRAWAL	Non-Executive - Independent Director	Member	17-09-2024		

Sta	ikeholders F	Relationship Committee					
		Whether the Stakeholders	Yes				
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	01797300	HEMANT KASLIWAL	Non-Executive - Independent Director	Chairperson	17-09-2024		
2	09675176	RAKESH AGRAWAL	Non-Executive - Independent Director	Member	09-08-2022		
3	05167866	ATEET AGRAWAL	Non-Executive - Independent Director	Member	17-09-2024		

Ris	Risk Management Committee											
	Whether the Risk Management Committee has a Regular Chairperson											
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks					

Co	Corporate Social Responsibility Committee											
	Whether the Corporate Social Responsibility Committee has a Regular Chairperson											
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks					

	Otl	ner Committee					
Ī	Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

				Anne	exure 1							
Ann	Annexure 1											
III.	II. Meeting of Board of Directors											
Dis	sclosure of notes board of directo											
Sr. No.	Date(s) of meeting (if any) in the previous quarter	Date(s) of meeting (if any) in the current quarter	Maximum gap between any two consecutive (in number of days)	Notes for not providing Date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors as on date of the meeting	Number of Directors present* (All directors including Independent Director)	No. of Independent Directors attending the meeting*				
1	12-11-2024				Yes	6	6	3				
2		02-01-2025	50		Yes	6	6	3				
3		11-02-2025	39		Yes	6	6	3				
4		01-03-2025	17		Yes	6	6	3				
5		29-03-2025	27		Yes	6	6	3				

## Annexure 1

## IV. Meeting of Committees

		Disclos	sure of notes of	n meeting of	f committee	s explanatory				
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
1	Audit Committee	12-11-2024				Yes	3	3	3	2
2	Audit Committee	11-02-2025	90			Yes	3	3	3	2
3	Audit Committee	24-03-2025	40			Yes	3	3	3	2
4	Stakeholders Relationship Committee	20-12-2024				Yes	3	3	3	2
5	Stakeholders Relationship Committee	06-01-2025	16			Yes	3	3	3	2
6	Stakeholders Relationship Committee	20-01-2025	13			Yes	3	3	3	2

					Annexu	re 1				
IV	Meeting of Co	ommittees								
Sr	Name of Committee	Date(s) of meeting (Enter dates of Previous quarter and Current quarter in chronological order)	Maximum gap between any two consecutive (in number of days)	Name of other committee	Reason for not providing date	Whether requirement of Quorum met (Yes/No)	Total Number of Directors in the Committee as on date of the meeting	Number of Directors Present (All Directors including Independent Director)	No. of Independent Directors attending the meeting*	No. of members attending the meeting (other than Board of Directors)
7	Stakeholders Relationship Committee	04-02-2025	14			Yes	3	3	3	2
8	Stakeholders Relationship Committee	28-02-2025	23			Yes	3	3	3	2

	Annexure 1	
V	Affirmations	
Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	Yes
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	Yes
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	Yes
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	Yes
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 1000 listed entities)	NA
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	Yes
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	Yes

	Anno	exure 1
Sr	Subject	Compliance status
1	Name of signatory	Ankita Jain
2	Designation	Chief Financial Officer

	I. Disclosure on website in terms of LODR Regulation					
Sr						
Sr	Item	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.	Web address		
	As per regulation 46(2) of the LODR:					
1.1	Details of business	Yes		www.raajmedisafeindia.com		
1.2	Memorandum of Association and Articles of Association	Yes		www.raajmedisafeindia.com		
1.3	Brief profile of board of directors including directorship and full-time positions in body corporates	Yes		www.raajmedisafeindia.com		
2	Terms and conditions of appointment of independent directors	Yes		www.raajmedisafeindia.com		
3	Composition of various committees of board of directors	Yes		www.raajmedisafeindia.com		
4	Code of conduct of board of directors and senior management personnel	Yes		www.raajmedisafeindia.com		
5	Details of establishment of vigil mechanism/ Whistle Blower policy	Yes		www.raajmedisafeindia.com		
6	Criteria of making payments to non-executive directors	Yes		www.raajmedisafeindia.com		
7	Policy on dealing with related party transactions	Yes		www.raajmedisafeindia.com		
8	Policy for determining 'material' subsidiaries	NA				
9	Details of familiarization programmes imparted to independent directors	Yes		www.raajmedisafeindia.com		
10	Email address for grievance redressal and other relevant details	Yes		www.raajmedisafeindia.com		
11	Contact information of the designated officials of the listed entity who are responsible for assisting and handling investor grievances	Yes		www.raajmedisafeindia.com		
12	Financial results	Yes		www.raajmedisafeindia.com		
13	Shareholding pattern	Yes		www.raajmedisafeindia.com		
14	Details of agreements entered into with the media companies and/or their associates	NA				

An	nexure II to be submitted by listed entity at the end of the financial year (fo	r the	whole of financial year)
	I. Disclosure on website in terms of LODR Regulation		
Sr			
	As per regulation 46(2) of the LODR:		
15.1	(I) Schedule of analyst or institutional investor meet (II) Presentations prepared by the listed entity for analysts or institutional investors meet, post earnings or quarterly calls prior to beginning of such events.	NA	
15.2	Audio recordings, video recordings, if any, and transcripts of post earnings or quarterly calls, by whatever name called, conducted physically or through digital means	NA	
16	New name and the old name of the listed entity	NA	
17	Advertisements as per regulation 47 (1)	Yes	www.raajmedisafeindia.com
18	Credit rating or revision in credit rating obtained	NA	
19	Separate audited financial statements of each subsidiary of the listed entity in respect of a relevant financial year	NA	
20	Secretarial Compliance Report	Yes	www.raajmedisafeindia.com
21	Materiality Policy as per Regulation 30 (4)	Yes	www.raajmedisafeindia.com
22	Disclosure of contact details of KMP who are authorized for the purpose of determining materiality as required under regulation 30(5)	Yes	www.raajmedisafeindia.com
23	Disclosures under regulation 30(8)	Yes	www.raajmedisafeindia.com
24	Statements of deviation(s) or variations(s) as specified in regulation 32	NA	
25	Dividend Distribution policy as per Regulation 43A(1)	NA	
26.1	Annual return as provided under section 92 of the Companies Act, 2013	Yes	www.raajmedisafeindia.com
26.2	Employee Benefit scheme documents framed in terms of SEBI (SBEB) Regulations, 2021	NA	
27	Confirmation that the above disclosures are in a separate section as specified in regulation 46(2)	Yes	www.raajmedisafeindia.com
28	Compliance with regulation 46(3) with respect to accuracy of disclosures on the website and timely updating	Yes	www.raajmedisafeindia.com

	1	Annexure II		
II.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
1	Independent director(s) have been appointed in terms of specified criteria of 'independence' and/or 'eligibility'	16(1)(b)	Yes	
2	Board composition	17(1), 17(1A) & 17(1C), 17(1D) & 17(1E)	Yes	
3	Meeting of Board of directors	17(2)	Yes	
4	Quorum of Board meeting	17(2A)	Yes	
5	Review of Compliance Reports	17(3)	Yes	
6	Plans for orderly succession for appointments	17(4)	Yes	
7	Code of Conduct	17(5)	Yes	
8	Fees/compensation	17(6)	Yes	
9	Minimum Information	17(7)	Yes	
10	Compliance Certificate	17(8)	Yes	

Annexure II						
II. Annual Affirmations						
Sr Partic	culars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non- compliance may be given here.		
11 Risk	Assessment & Management	17(9)	NA			
12 Perfo	ormance Evaluation of Independent Directors	17(10)	Yes			
13 Reco	ommendation of Board	17(11)	Yes			
14 Maxi	imum number of Directorships	17A	Yes			
15 Comp	position of Audit Committee	18(1)	Yes			
16 Meet	ting of Audit Committee	18(2)	Yes			
	of Audit Committee and information to be ewed by the audit committee	18(3)	Yes			
	position of nomination & remuneration mittee	19(1) & (2)	Yes			
	rum of Nomination and Remuneration imittee meeting	19(2A)	Yes			
	ting of Nomination and Remuneration mittee	19(3A)	Yes			

		Anne	xure II	
II.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
21	Role of Nomination and Remuneration Committee	19(4)	Yes	
22	Composition of Stakeholder Relationship Committee	20(1), 20(2) & 20(2A)	Yes	
23	Meeting of Stakeholders Relationship Committee	20(3A)	Yes	
24	Role of Stakeholders Relationship Committee	20(4)	Yes	
25	Composition and role of risk management committee	21(1),(2),(3),(4)	NA	
26	Meeting of Risk Management Committee	21(3A)	NA	
27	Quorum of Risk Management Committee meeting	21(3B)	NA	
28	Gap between the meetings of the Risk Management Committee	21(3C)	NA	
29	Vigil Mechanism	22	Yes	
30	Policy for related party Transaction	23(1), (1A), (5), (6), & (8)	Yes	

	Annexu	re II		
II.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
31	Prior or Omnibus approval of Audit Committee for all related party transactions	23(2), (3)	Yes	
32	Approval for material related party transactions	23(4)	Yes	
33	Disclosure of related party transactions on consolidated basis	23(9)	Yes	
34	Composition of Board of Directors of unlisted material Subsidiary	24(1)	NA	
35	Other Corporate Governance requirements with respect to subsidiary of listed entity	24(2),(3), (4),(5) & (6)	NA	
36	Alternate Director to Independent Director	25(1)	Yes	
37	Maximum Tenure	25(2)	Yes	
38	Appointment, Re-appointment or removal of an Independent Director through special resolution or the alternate mechanism	25(2A)	Yes	
39	Meeting of independent directors	25(3) & (4)	Yes	
40	Familiarization of independent directors	25(7)	Yes	

	Annexure II			
П.	Annual Affirmations			
Sr	Particulars	Regulation Number	Compliance status (Yes/No/NA)	If status is "No" details of non-compliance may be given here.
41	Declaration from Independent Director	25(8) & (9)	Yes	
42	Directors and Officers insurance	25(10)	NA	
43	Confirmation with respect to appointment of Independent Directors who resigned from the listed entity	25(11)	Yes	
44	Memberships in Committees	26(1)	Yes	
45	Affirmation with compliance to code of conduct from members of Board of Directors and Senior management personnel	26(3)	Yes	
46	Policy with respect to Obligations of directors and senior management	26(2) & 26(5)	Yes	
47	Approval of the Board and shareholders for compensation or profit sharing in connection with dealings in the securities of the listed entity	26(6)	Yes	
48	Vacancies in respect Key Managerial Personnel	26A(1) & 26A(2), 26A(3)	Yes	
	Any other information to be provided - Add Notes			

	Ann	exure II
1	Name of signatory	Ankita Jain
2	Designation	Chief Financial Officer

Annexure II				
III. Affirmations				
Sr Particulars	Compliance status (Yes/No/NA)			
The Listed Entity has approved Material Subsidiary Policy and the Corporate Governance requirements with respect to subsidiary of Listed Entity have been complied	NA			
Any other information to be provided				

	Annexure II				
1	Name of signatory	Ankita Jain			
2	Designation	Chief Financial Officer			

Details of Cyber security incidence					
Whether as per Regulation 27(2)(ba) of SEBI (LODR) Regulations, 2015 there has been cyber security incidents or breaches or loss of data or documents during the quarter					
Number of cyber security incidence or breaches or loss of data event occurred during the quarter					
Sr.	Date of the event	Brief details of the event			

Signatory Details				
Name of signatory	Ankita Jain			
Designation of person	Chief Financial Officer			
Place	Ujjain			
Date	28-04-2025			

Investor Grievance Details	
No. of investor complaints pending at the beginning of Quarter	0
No. of investor complaints received during the Quarter	0
No. of investor complaints disposed off during the Quarter	0
No. of investor complaints those remaining unresolved at the end of the Quarter	0